WednesdayMay 31, 2023 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Finalizes DehydraTECH(TM)-CBD Batch Manufacturing for IND Filing This Summer and FDA Phase 1b Trial Commencement in October 2023

Lexaria just announced the completion of batch manufacturing of its patented DehydraTECH(TM)-processed CBD and placebo materials for its FDA Phase 1b HYPER-H23-1 human clinical study This is in line with the company’s IND filing with the FDA, which it looks to complete this summer, with potential authorization within 60 days FDA authorization will mark the commencement of Phase 1b trial patient dosing, with the study evaluating the safety and tolerability of DehydraTECH-CBD in hypertensive patients Filling into capsules of the manufactured DehydraTECH-CBD is expected to be completed before the end of this month, after which analytical release and stability testing…

Continue Reading

TuesdayMay 30, 2023 10:30 am

Mullen Automotive Inc. (NASDAQ: MULN) Strengthens Position in Growing EV Market

The market for EVs has grown rapidly in recent years and is expected to continue growing at a fast pace over the coming decade MULN’s two manufacturing facilities are gearing up for increased production volume The company is meeting noteworthy milestones with each of its EV brands As the EV market steadily rises in the coming years, Mullen Automotive (NASDAQ: MULN) is positioning itself to be a strong player in the space. The Southern California–based automotive company recently released a corporate update outlining the impressive growth it has seen in the past few months ( “The market for electric vehicles…

Continue Reading

FridayMay 26, 2023 9:45 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Shareholders Approve Board Appointments Amid Push for Diversity; Vote to Endorse 6 Agenda Items in 2023 Annual Shareholder Meeting

Lexaria held its virtual 2023 Annual Shareholders meeting on May 9, 2023 On the agenda were the election of six director nominees, the ratification of the appointment of the company’s independent registered public accounting firm, and the approval of a one-time repricing of specific issued stock options, among others All items presented received approval, with the highest approval percentage standing at 97.6% and the lowest at 63.1% The meeting presented an opportunity for Lexaria to evaluate areas of expertise that would provide additional benefits to the company and its shareholders while also adding diversity to its board Lexaria Bioscience (NASDAQ:…

Continue Reading

TuesdayMay 23, 2023 11:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Completes $2 Million Public Offering Consisting of Common Shares and Accompanying Warrants

Lexaria recently completed its 2,106,000-unit public offering at $0.95 per share – representing proceeds totaling over $2 million gross in support of the company’s growth Maxim Group LLC is acting as the sole placement agent in connection with Lexaria’s offering Earlier the company was granted four new patents, bringing its total to 32 granted and many more pending worldwide for its patented DehydraTECH(TM) technology Lexaria is currently seeking IND status from the FDA for use of DehydraTECH-processed CBD with hypertension and expects to begin dosing a new human clinical trial in October 2023 Lexaria Bioscience (NASDAQ: LEXX), a global innovator…

Continue Reading

MondayMay 22, 2023 9:45 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Completes Dosing in Human Oral Nicotine Study, Hopes to Facilitate More Satisfying Experience with DehydraTECH(TM)-Processed Oral Nicotine

Lexaria recently reported that dosing of the targeted 36 volunteers in its human clinical oral nicotine study, NIC-H22-1, had been completed The company hopes to demonstrate that its DehydraTECH(TM)-processed nicotine absorbs more quickly and more efficiently into the human bloodstream than leading oral nicotine brands Through previous animal testing, Lexaria showed that DehydraTECH-nicotine was up to 10x to 20x faster in delivering comparable levels of nicotine and delivered up to 6-fold higher levels of nicotine into blood plasma than concentration-matched controls If the findings from the human study replicate a similarly improved performance, Lexaria believes this could facilitate a more…

Continue Reading

FridayMay 19, 2023 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Pivotal Milestones Concerning DehydraTECH(TM) Technology, Including IND Application Plans

Lexaria's patented DehydraTECH(TM) technology enhances drug bioavailability, making it useful for a wide range of product formats, including pharmaceuticals, neutraceuticals, consumer packaged goods, and over-the-counter pills, capsules, tablets, and oral suspensions The company is currently exploring the potential benefits of DehydraTECH related to several molecules including, purified nicotine, CBD, antiviral drugs, human hormones, and PDE5 inhibitors Lexaria recently announced the completion of its diabetes animal study DIAB-A22-1 with at least three positive outcomes using DehydraTECH-CBD California-based InClin, Inc. has been awarded the contract for clinical research organization services for the expected upcoming FDA-registered, U.S. Phase 1b IND hypertension study, HYPER-H23-1…

Continue Reading

WednesdayMay 17, 2023 9:45 am

Genprex Inc. (NASDAQ: GNPX) Research Collaborators Present Positive Preclinical Data at American Association of Cancer Research 2023 Annual Meeting

Positive preclinical data was presented for the NPRL2 tumor suppressor gene The studies used Genprex’s non-viral ONCOPREX(R) Nanoparticle Delivery System in KRAS/STK11 mutant anti-PD1 resistant metastatic human non-small cell lung cancer (“NSCLC”) humanized mouse models Validates ONCOPREX(R) platform’s ability to deliver other tumor suppressor genes to potentially address multiple types of cancer ONCOPREX(R) Nanoparticle Delivery System is the novel non-viral platform being used for the company’s lead drug candidate, REQORSA(R) Immunogene Therapy, initially targeting lung cancer Genprex (NASDAQ: GNPX), A cutting-edge gene therapy company striving to improve the lives of cancer and diabetes patients through the creation of groundbreaking treatments,…

Continue Reading

TuesdayMay 16, 2023 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Kicks Off FDA IND Filing Process with Granted CRO Contract to California-Based InClin, Inc.

Lexaria just awarded InClin, Inc. the contract for CRO services, in a move that lines up with the company’s upcoming FDA-registered, U.S. Phase 1b IND hypertension study, HYPER-H23-1 InClin will manage the study in the form of clinical site evaluation and selection, project management, personnel, site training, and more Patient dosing is set to kick off as soon as possible once the expected FDA IND filing and review is completed, which Lexaria hopes will be done this summer HYPER-H23-1 will be Lexaria’s most ambitious study yet, and upon its completion, it will move the company closer to FDA approval of…

Continue Reading

MondayMay 15, 2023 9:00 am

Freight Technologies Inc. (NASDAQ: FRGT) Secures Participation of Whirlpool on its Platform, Cementing its Position as a Trusted Logistics Partner

Freight Technologies (Fr8Tech) just secured the participation of Whirlpool, one of the world’s largest home appliance manufacturers, in what the CEO, Javier Selgas, regards as a “huge milestone” for the company This move reflects Fr8Tech’s commitment to creating innovative logistics solutions and pushing the envelope concerning improving B2B cross-border shipping and domestic shipping within the USMCA region Rafael Flores, the Sr. Manager of Logistics at Whirlpool Mexico, lauded Fr8Tech’s offering, citing how it “aligned with Whirlpool’s vision of improving life at home and being closer to our customers” Mr. Selgas expressed his optimism about the new engagement, noting how confident…

Continue Reading

FridayMay 12, 2023 9:00 am

Cepton, Inc.’s (NASDAQ: CPTN) Confidence Rises as Lidar Becomes Critical Element in Road Safety Toolbox Amid Record High Pedestrian Fatalities

The latest data uncovers a troubling reality that existing technologies have limitations in mitigating road accidents; pedestrian deaths reached a grim milestone not seen in four decades As the need for better transportation safety becomes more urgent than ever before, innovative solutions are needed; the latest research shows that combining lidar, camera, and radar can achieve the greatest potential for eliminating fatalities As a company leading the charge in designing next generation lidar technology, Cepton is committed to prioritizing safety in automated vehicles to enhance the traffic experience for today’s drivers, passengers, and pedestrians The latest figures from the United…

Continue Reading

Contact us: (310) 299-1717